Alzheimer’s treatment donanemab is not a ‘miracle drug’ – not providing it on the NHS is the right choice
There is a lot of outrage that the new Alzheimer’s drug donanemab is being refused on the NHS. But there are good reasons for ...
Medpage Today on MSN4d
Brain Edema Risk May Be Lower With Modified Donanemab Dosing
The standard dosing regimen was 700 mg of donanemab for the first three infusions, then 1,400 mg for each infusion after that ...
Hosted on MSN9d
Donanemab: What is the new Alzheimer’s drug rejected for use on the NHS
The drug Donanemab has been found to slow the progression of Alzheimer’s disease. Despite this is has been rejected for ...
Modified Titration of Donanemab Demonstrated Reduction of ARIA-E in Early Symptomatic Alzheimer's Disease Patients in Phase 3b study
Eli Lilly and Company (NYSE: LLY) today announced positive results from the TRAILBLAZER-ALZ 6 Phase 3b study, showing a ...
Monthly Prescribing Reference3d
Study Shows Modified Donanemab Titration Regimen Cuts Risk of ARIA-E
Modified titration was associated with a 41% lower relative risk of ARIA-E than the standard dosing regimen. Topline results were announced from a phase 3b trial evaluating various dosing regimens of ...
News Medical on MSN6d
MHRA greenlights donanemab for early stage Alzheimer’s disease
The Medicines and Healthcare products Regulatory Agency (MHRA) has today, 23 October 2024, approved a license for the ...
STAT9d
U.K.’s cost-effectiveness agency says Alzheimer’s drug donanemab does not provide good value
For the second time in recent months, a U.K. agency said the limited benefits of a new Alzheimer’s drug do not justify its ...
Medscape3d
Expert Guidance Issued for Real-World Use of Donanemab
An expert workgroup has developed the first appropriate use recommendations (AURs) for real-world use of the antiamyloid donanemab (Kisunla). “The role of appropriate use recommendations are to ...
Eli Lilly says Donanemab redudced ARIA-E in early Alzheimer’s patients
Eli Lilly (LLY) announced “positive results” from the TRAILBLAZER-ALZ 6 Phase 3b study, showing a reduction in amyloid-related ...
Alzheimer’s drug approved in the UK, but it won’t be available on the NHS – here’s why
The UK’s drugs regulator – the MHRA – has approved the Alzheimer’s drug donanemab, but it won’t be available on the NHS.
National Institute for Health and Care Excellence9d
New Alzheimer’s treatment donanemab does not currently demonstrate value for the NHS says NICE
Donanemab (also called Kisunla and made by Eli Lilly) has been licensed today by the MHRA for treatment of mild cognitive impairment or mild dementia due to Alzheimer’s disease in some adults. It is a ...
Alzheimer's Society10d
Alzheimer's Society responds to MHRA and NICE announcements on donanemab
The MHRA have approved donanemab for the treatment of Alzheimer’s disease. However, NICE does not recommend use on the NHS ...